Pancreatic cancer drug approval: FDA OKs Revolution Medicines' daily pills

Key Points:

• The FDA has approved daraxonrasib (brand name Rasonque), a novel pill targeting mutated KRAS proteins in over 90% of pancreatic cancers, marking a significant advancement in treating this deadly disease.
• In clinical trials involving 500 patients with metastatic pancreatic cancer resistant to prior treatments, daraxonrasib nearly doubled median survival to 13.2 months compared to 6.7 months with chemotherapy, with manageable side effects.
• Pancreatic cancer remains highly lethal due to late detection and limited treatment options, with a five-year survival rate of just 13%, making this new drug the most effective option available to date.
• The drug’s approval was expedited by over six months following strong public interest, including endorsements from patients like former Senator Ben Sasse, and it represents the first successful targeting of previously "undruggable" KRAS mutations.
• Revolution Medicines plans to explore this molecular glue technology for other cancers, such as lung cancer, potentially opening new avenues for treating multiple tumor types.